Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Venture Investment Plummets In 2009 As VCs Retrench

This article was originally published in The Pink Sheet Daily

Executive Summary

Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.

You may also be interested in...

Ironwood Swings For The IPO Fences

The developer of a Phase III constipation drug wants to raise nearly $270 million in the first week of February. Will it hit a financing home run or strike out?

Venture Data Continues To Haunt The Biotech Landscape

Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.

Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO

Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts